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a  b  s  t  r  a  c  t
Background:  Takotsubo  cardiomyopathy  (TC)  is  an acute cardiac  syndrome  characterized  by  transient  left
ventricular  dysfunction  and  relatively  good  prognosis  after discharge.  However,  cardiac  complications
during  hospitalization  remain  to be fully  determined.  We  attempted  to  determine  features  characterizing
patients  with  adverse  clinical  outcome  by  comparing  those  with  cardiac  complication  and  without  cardiac
complication  during  hospitalization.
Methods  and results:  We  investigated  107  patients  with  TC  from  the  Tokyo  CCU  Network  database,  com-
prising  67 cardiovascular  centers  in  the  metropolitan  area  during  January  1 to December  31, 2010.  Cardiac
complications  were  deﬁned  as  cardiac  death,  pump  failure  (Killip  grade  ≥  II), sustained  ventricular  tachy-
cardia or  ﬁbrillation  (SVT/VF),  and  advanced  atrioventricular  block  (AVB).  Cardiac  complications  were
observed  in 41  patients  (37 pump  failure  complicated  by  3 cardiac  deaths  and 2 SVT/VF  and  2  AVB  with-
out  pump  failure),  and  there  was  no cardiac  complication  in  the remaining  66 patients.  There  was  no
difference  in  age,  peak  creatinine  kinase  level,  C-reactive  protein  level  and  ST  elevation  on  electrocar-
diogram.  Multiple  logistic  regression  analysis  showed  that  white  blood  cell count  (p = 0.039)  and  brain
natriuretic  peptide  (p = 0.001)  were  independent  predictors  of  in-hospital  adverse  cardiac  complications.
Conclusions:  Cardiac  complications  are relatively  high  in patients  with  TC during  hospitalization.  High
white  blood  cell  count  and  brain  natriuretic  peptide  level  are  associated  with poor  clinical  outcome  in
3  Jap
patients  with  TC.
© 201
ntroductionTakotsubo cardiomyopathy (TC) is one of the common
ardiomyopathies featuring characteristic morphology on car-
iac imaging [1–3]. TC usually has a good prognosis, but in
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rare instances, it may  be associated with cardiac complica-
tions such as cardiac rupture, thrombus formation resulting in
thromboembolic event, heart failure, various arrhythmias, and
death [4,5]. However the whole nature of clinical presentation
and hospital course remains ill-deﬁned, because large clinical
databases are lacking. Tokyo CCU Network database is an ongo-
ing multicenter registry that prospectively collects information
on emergency admissions to acute cardiac care facilities [6,7].
The database, comprising 67 large volume cardiovascular cen-
ters in the metropolitan area, provides us a unique opportunity
to characterize fundamental features of the disease. This study
sought to characterize the epidemiology and predictors of cardiac
vier Ltd. All rights reserved.





















































Number of patients 107
Age 73.9 ± 11.1 years
Women  82 (76.6%)




No stress 34 (31.7%)
Past history of TC 5
Systolic blood pressure 128 ± 23 mmHg
Diastolic pressure 71 ± 13 mmHg
Heart rate 82 ± 31 bpm
Arterial O2 saturation 96.0 ± 4.8%
Killip classiﬁcation
I  70 (65.4%)
II 25 (23.4%)
February, 11 in March, 13 in September, 14 in October, and 12 in
November (Fig. 1). Data were not available for 4 patients as to when
TC occurred.70 T. Murakami et al. / Journal
omplications during hospitalization with TC from Tokyo CCU Net-
ork database.
ethods
nclusion criteria with TC
We  deﬁned TC according to the following 4 criteria which have
een proposed by the Mayo Clinic, Rochester, MN,  USA [8]. (1)
ransient hypokinesis, akinesis, or dyskinesis of the left ventricular
idsegments with or without apical involvement; the regional wall
otion abnormalities extend beyond a single epicardial vascular
istribution; a stressful trigger is often, but not always present. (2)
bsence of obstructive coronary disease or angiographic evidence
f acute plaque rupture. (3) New electrocardiographic abnormal-
ties (either ST-segment elevation and/or T-wave inversion) or
odest elevation of cardiac troponin. (4) Absence of pheochromo-
ytoma or myocarditis.
tudy subjects
In 2010, 23,063 patients, including 4653 with acute myocardial
nfarction, 5326 with acute heart failure, and 918 with acute aortic
issection, were admitted to the 67 large-volume cardiovascular
enters in the metropolitan area which participated in the Tokyo
CU Network. We  examined 107 patients with TC from the Tokyo
CU Network database during January 1 to December 31, 2010.
ata acquisition
The following data on TC patients were collected: (1) Elapsed
ime from the onset to hospitalization. (2) Clinical proﬁles includ-
ng chief complaint, age, preceding stresses, and past history of TC.
3) Initial vital signs such as systolic and diastolic blood pressure
n the emergency room or cardiac care unit, arterial O2 saturation,
eart rate, and Killip classiﬁcation [9]. (4) Electrocardiogram on
dmission [10]. QT prolongation was deﬁned as QTc ≥ 0.44 s. (5)
aboratory data on admission and peak creatinine kinase (CK) and
ts MB  isozyme during hospitalization. (6) Echocardiographic ﬁnd-
ngs on admission. Left ventricular ejection fraction (LVEF) was
valuated by modiﬁed Simpson method using echocardiography
erformed on admission. Left ventricular outﬂow tract obstruction
as considered signiﬁcant if more than 30 mmHg [11]. (7) Car-
iac catheterization ﬁnding obtained from coronary angiography,
eft venticulography, and endomyocardial biopsy if performed. (8)
rrhythmic events during hospitalization. (9) Therapeutic proce-
ures during hospitalization, such as mechanical cardiorespiratory
upport and cardiovascular drugs during hospitalization. (10) In-
ospital mortality.
ardiac complications during hospitalization
Cardiac complications during hospitalization were deﬁned as
ardiac death, cardiac rupture, thromboembolism, pump failure
Killip grade ≥ II), sustained ventricular tachycardia or ventricular
brillation (SVT/VF), and advanced atrioventricular block (AVB).
e attempted to characterize factors predicting clinical outcome
y comparing between patients with cardiac complications and
hose without complications during hospitalization.
tatistical analysisData are expressed as mean ± SD. Differences between all vari-
bles were analyzed using Student’s t-test. Differences between
ategorical variables were analyzed using the chi-square test. A p-
alue <0.05 was considered signiﬁcant. Stepwise multiple logisticIII 5 (4.7%)
IV  7 (6.5%)
regression analysis was performed to predict in-hospital cardiac
complications.
Results
Data on 107 patients with TC were collected. Elapsed time from
the onset to hospitalization was shorter than 24 h in 81.8%, and
95.9% of the study population were admitted within 72 h. There
were 4 patients who presented with symptoms after surgical pro-
cedure (details unknown).
The main chief complaint was chest pain (54.2%). Almost all
cases were preceded by physical (39.3%) or emotional (29.0%)
stresses. Prior history of TC was noted in 5 patients. In recurrent
cases, elapsed time from prior episode to the attack was  14 months,
42 months, and 14 months, respectively. In the remaining 2 cases,
data were not available as to when prior episodes of TC occurred. In
these recurrent cases, emotional stress was  identiﬁed as a precip-
itating factor in 4 patients. Seventy patients (65.4%) showed Killip
class I, and the remaining 37 patients (34.6%) showed class II or
more (Table 1). There was  ST segment elevation in 79 patients
(73.8%), negative T in 77 patients (72.0%), and QT prolongation in
50 patients (46.7%).
There was a seasonal variation, showing 10 TC patients inFig. 1. Seasonal distribution of onset of takotsubo cardiomyopathy is shown. There
was a tendency for bimodal peaks in spring and autumn.
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Table  2
In-hospital death and its causes.
Case No. Age Gender Type Preceding stress Killip Cause Time to death WBC  (/l)
1 80 Female Apical Dyspnea II Respiratory failure 13 days 7400
2  88 Female Apical None II Cerebral embolism 13 days 9600
3  88 Female Apical Hypoxia II Interstitial pneumonia 56 days 8600
4  76 Male Apical Hypoglycemia IV Multiple organ failure 8 days 1400
5  79 Female Apical Infection III Sepsis 3 days 5600
6  66 Male Apical Emotional IV Cardiogenic shock 2 days 8330

















































considerable number of patients who experienced adverse clinical
events during hospitalization. We  found that WBC  count on admis-
sion as well as plasma BNP level were independent predictors of
adverse clinical outcome.
Table 3
Differences in clinical variables between patients with cardiac complications and
those without complications.
Cardiac complication Present (n = 41) Absent (n = 66) p-Value
Age 75.2 ± 10.4 72.9 ± 11.6 0.289
Female n = 29 (70.7%) n = 53 (80.3%) 0.144
WBC  (/l) 11189 ± 4516 9020 ± 3352 0.005
Peak CK (IU/l) 553 ± 710 486 ± 1024 0.780
CRP  (mg/dl) 2.63 ± 3.75 1.90 ± 4.25 0.378
BUN/Cr 26.0 ± 9.6 29.2 ± 36.5 0.53
BNP  (pg/ml) 1125 ± 1245 376 ± 764 0.004
LVEF 49.3 ± 15.4 56.6 ± 14.1 0.0308  70 Female Apical Emotional 
9  76 Female Apical Hemodialysis 
ime, duration from occurrence of takotsubo cardiomyopathy to death; DIC, dissem
There was a mild elevation of creatinine kinase (338 ± 554 IU/l)
nd its MB fraction (27 ± 40 IU/l), white blood cell count (WBC,
676 ± 4006/l),  and C-reactive protein (CRP, 2.19 ± 4.04 mg/dl)
evel on admission. Brain natriuretic peptide (BNP) level was
lso moderately increased (656 ± 1622 pg/ml). Blood urea nitrogen
BUN) was 23 ± 16 mg/dl, creatinine (Cr) was 1.49 ± 3.20 (includ-
ng 2 hemodialysis patients). Asparatate aminotransferase was
2 ± 53 IU/l, alanine aminotransferase was 29 ± 26 IU/l, and total
ilirubin was 0.82 ± 0.63 mg/dl. Cardiac troponin was  measured in
3 cases, of whom 78 cases (83.9%) were positive.
Echocardiographic ﬁndings showed that LVEF was  54.1 ± 14.9%,
eft ventricular end-diastolic dimension was 43 ± 8 mm,  end-
ystolic dimension was 29 ± 9 mm,  and left atrial dimension was
3 ± 7 mm.  Apical ballooning type was predominant (91.6%, n = 98),
ut mid-ventricular type (3.7%, n = 4), basal inverted type (2.8%,
 = 3), and atypical type (1.9%, n = 2) were also noted. Signiﬁcant
eft ventricular outﬂow obstruction was noted in 4 patients, and
oderate or more degree of mitral regurgitation was observed in 5
atients. There were 5 patients who exhibited pericardial effusion
ith no evidence of cardiac rupture.
Emergency catheterization was performed in 92 cases (86.0%).
igniﬁcant coronary arterial stenosis was recognized in 9 patients,
f whom single-vessel disease was present in 6 patients, double-
essel disease in 2 patients, and triple-vessel disease in 1 patient,
lthough these coronary lesions did not account for the wall motion
bnormality. There was no evidence suggesting plaque rupture.
eft ventriculography was performed in only 59 cases. Provoca-
ion of coronary spasm using acetylcholine was  attempted in only
 cases, with positive in 1 case and negative in the remaining 1 case.
ndomyocardial biopsy was not performed in any patients.
Atrial ﬂutter or ﬁbrillation was observed in 13 patients (12.1%).
VT/VF was noted in 3 patients (1 case with pump failure and 2 cases
ithout pump failure). AVB was observed in 2 patients at the time
f hospitalization, requiring permanent pacemaker implantation
n 1 patient. During the hospital course, 19.6% of cases necessi-
ated cardiac supportive therapies (inotropic agents, n = 16; pacing,
 = 2; intra-aortic balloon pumping, n = 3) and 13.1% cases needed
espiratory support therapies (mechanical ventilation, n = 7; non-
nvasive positive pressure ventilation, n = 7).
Nine patients (8.4%) died during the hospital course. There were
 cardiovascular deaths (3.7%) including heart failure death in 2,
eath due to cardiogenic shock in 1, and death due to cerebral
mbolism in 1 (Table 2). In the remaining 5 patients, the primary
auses of death were non-cardiovascular, but all cases were com-
licated by heart failure. WBC  count tended to be higher in patients
ith cardiovascular death than those with non-cardiovascular
eath (14,183 ± 7118/l  vs. 6866 ± 3698/l,  p = 0.08).
Cardiac complications were observed in 41 patients, and there
as no complication in the remaining 66 patients. Pump failure
as noted in 37 patients. There were 2 patients with SVT/VF and
 patients with AVB who did not have pump failure complica-
ions. Three cardiac deaths were observed in patients who  had
ump failure complications. Among them, 1 patient also had SVTIV Heart failure 12 days 14,800
II DIC 32 days 11,330
d intravascular coagulation; WBC, white blood cell count.
complications. One patient with pump failure complications, died
of cerebral embolism. There was no cardiac rupture.
Ninety-eight patients survived the hospital course. At discharge,
angiotensin-converting enzyme inhibitors or angiotensin II type 1
receptor blockers, beta-blocker, and diuretics were prescribed in
48.0%, 25.5%, and 20.4% of the study population, respectively. No
digitalis or inotropic agents were given.
There was no difference in age (75 ± 10 years vs. 72 ± 11
years, p = 0.289), female gender (70.7% vs. 80.3%, p = 0.144),
peak CK level (553 ± 710 IU/l vs. 486 ± 1024 IU/l, p = 0.780), CRP
level (2.63 ± 3.75 mg/dl vs. 1.90 ± 4.25 mg/dl, p = 0.378), BUN/Cr
(26.0 ± 9.6 vs. 29.2 ± 36.5; p = 0.53), and ST elevation on electrocar-
diogram (68.3% vs. 75.8%, p = 0.398), between patients with compli-
cations and those without complications. WBC  (11,189 ± 4516/l
vs. 9020 ± 3352/l,  p = 0.005) and BNP (1125 ± 1245 pg/ml vs.
376 ± 764 pg/ml, p = 0.004) were higher in patients with cardiac
complications than those without. LVEF was  lower in patients with
complications than those without (49.3 ± 15.4% vs. 56.6 ± 14.1%,
p = 0.03) (Table 3). There was  no difference in gender, LVEF, WBC,
BNP, BUN/Cr, or CRP levels between patients with cardiac death and
those without cardiac death.
The median value of WBC, BNP, and LVEF were 9050/l,
203.7 pg/ml, and 56%, respectively. Stepwise multiple logistic
regression analysis was  performed using the median value of WBC,
BNP, and LVEF. We  found that higher WBC  (odds ratio = 2.52,
95% CI = 1.05–6.06, p = 0.039) and BNP (odds ratio = 4.92, 95%
CI = 1.97–12.3, p = 0.001) were independent predictors of cardiac
complications during hospitalization (Table 4).
Discussion
In this analysis of the database of TC collected from the Tokyo
CCU Network annual report, we demonstrated that there was  aST  elevation n = 28 (68.3%) n = 50 (75.8%) 0.398
WBC, white blood cell count; CK, creatinine kinase; CRP, C-reactive protein; BNP,
brain natriuretic peptide level; BUN, blood urea nitrogen; LVEF, left ventricular
ejection fraction on echocardiography.
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Table  4
Independent predictors of in-hospital adverse cardiac complications.
Odds ratio 95% conﬁdence interval p-Value
WBC  2.52 1.05–6.06 0.039
BNP  4.92 1.97–12.3 0.001




















































myocarditis also exhibits some degree of cellular inﬁltration onBC, white blood cell count; BNP, brain natriuretic peptide level; LVEF, left ventri-
ular ejection fraction on echocardiography.
pidemiology
Previous TC outcome data exhibited an increased incidence dur-
ng summer (June, July, and August) in Italy, winter in Switzerland,
nd in April in France [12]. The Tokyo CCU Network database indi-
ated there was an increased incidence both during the spring and
utumn. Although there was a difference in the seasonal occurrence
mong various regions, the reason why there was such a difference
annot be explained properly. Further investigation is needed to
onﬁrm this issue.
Five patients (4.7%) showed recurrence of TC. Previous reports
ave shown that the percentage of recurrence ranged from 1.7% to
.0% [13,14]. The recurrence of TC in four of the ﬁve patients was
receded by emotional stress. Unfortunately, data on prior med-
cations before admission were not available in this Tokyo CCU
etwork database. The small number of patients who experienced
ecurrence and limited information on prior medications failed to
llow meaningful statistical analysis of factors predicting the recur-
ence.
Nine patients (8.4%) died during their hospital stay for various
easons including four cardiovascular deaths (3.7%). The previ-
us reports showed that the mortality rate during hospitalization
anged from 1.7% to 2.0% [13–15]. Overall mortality may be higher
n clinical practice, since non-cardiac death also comprises a con-
iderable part of in-hospital mortality in severely ill patients who
xperience TC. Actually, the morality rate in the present study
as relatively high compared with the previous reports. Tokyo
CU Network database included non-cardiac deaths, so the overall
ortality was higher than the previous reports. However, most of
on-cardiac deaths were precipitated by concomitant heart failure.
ecently, Brinjikji et al. reported clinical proﬁles in a large number
f patients with TC based on National Inpatient Database Samples
008 to 2009. They found that in-hospital mortality was  as high as
.2%, and most of the deaths were associated with underlying crit-
cal illnesses [16]. TC seems to be associated with high mortality
ates during hospitalization in the real world setting.
nﬂammation in TC
Cardiovascular magnetic resonance imaging demonstrated the
ontribution of an inﬂammatory process in the acute setting and
howed complete normalization of left ventricular function and
nﬂammatory parameters (T2-weighted image) [15,17,18]. Other-
ise, apart from their possible noxious role in the activation of
he inﬂammatory response, catecholamines could also contribute
o myocardial stunning in the absence of relevant myocardial
erfusion abnormalities [19,20]. In this regard, the inﬂammatory
rocess may  play a role in the pathophysiology of TC. CRP may
eﬂect acute inﬂammation, but the present study failed to show a
elationship with in-hospital cardiac complications. Alternatively,
n increase in WBC  count may  precede the CRP activation during
he early phase of inﬂammation. We  found that higher WBC  count
as associated with adverse clinical outcome, independently from
ardiac function as reﬂected by BNP level. WBC  count also tended
o be higher in patients with cardiovascular death than those with
on-cardiovascular death. There are numerous markers that reﬂectdiology 63 (2014) 269–273
inﬂammation, such as proinﬂammatory cytokines, oxidative stress,
etc. Although WBC  count may  be affected by various factors includ-
ing preceding stress, this may  be a simple conventional marker to
reﬂect the severity of TC. In this registry, 7 patients who experi-
enced infection were noted. However, the extent of leukocytosis
was associated with TC itself in the predominant cases.
BNP level
Plasma BNP level is a well-accepted marker for cardiac function.
The present study demonstrated this plasma level was moderately
increased in the overall population, but there was a wide varia-
tion in its distribution. Plasma BNP may  reﬂect mechanical wall
stress induced by abrupt onset of TC, as well as cardiac dysfunc-
tion. In this study, 25.2% patients with higher BNP level experienced
pump failure. As expected, we  found that higher BNP level was
associated with adverse clinical outcome. Morel et al. examined
the relationship between plasma BNP level and other neurohor-
mones as well as inﬂammatory markers, and found that there were
close correlations among these parameters [19]. It is possible that
sympathoadrenal activation during the early process of TC induces
hypertrophic signal and inﬂammatory response as reﬂected by
WBC and CRP levels [21], although an increase in plasma nor-
epinephrine concentration during the early phase after onset is
inconsistent in previous reports [22].
LV dysfunction
Cardiac dysfunction is a characteristic feature during the early
process of TC. We  found that pump failure was noted in 37 patients,
and this complication was  related directly or indirectly to in-
hospital mortality. In fact, LVEF was  lower in patients with cardiac
complications than those without complications. However, mul-
tivariate analysis failed to show the signiﬁcance of lower LVEF
in predicting clinical outcome. Since plasma BNP level may  be
associated with LVEF [21], potential signiﬁcance could have been
abolished by the presence of BNP.
Predischarge medications
Experimental studies have shown that combined alpha-
and beta-blocker, beta-blocker with intrinsic sympathomimetic
activity, and calcium channel blocker, azelnidipine, prevent stress-
induced cardiac dysfunction in rats [23,24]. In cases in whom the
left ventricular wall motion abnormalities remains, beta-blockers,
angiotensin-converting enzyme inhibitors, or angiotensin II type 1
receptor blockers are recommended [1]. In our registry, only 48.0%
patients were given angiotensin-converting enzyme inhibitors or
angiotensin II type 1 receptor blockers, and 25.5% patients were
given beta-blockers. Whether or not such medications affect clini-
cal course after discharge remains to be determined.
Study limitations
First, not all patients underwent catheterization, so the diag-
nosis of TC was  made according to the characteristic ﬁndings on
electrocardiography and echocardiography in several cases. Sec-
ond, WBC  count may be affected by various factors, such as infection
and preceding stress. Third, biopsy was  performed in none of the
study subjects. Cardiac magnetic resonance imaging in assessing
the presence of myocarditis was  performed in only four cases. Acutehistopathology and interstitial inﬂammation on T2 imaging in car-
diac magnetic resonance imaging, both of which mimic  TC. Lastly,
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onclusions
In this report from the Tokyo CCU Network database, cardiac
omplications were relatively high during hospitalization, and a
onsiderable number of patients died. High WBC  count and BNP
evel are associated with poor clinical outcome in patients with TC.
ong-term follow-up and factors inﬂuencing life expectancy are
ecessary to further clarify its clinical features.
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